retatrutide clinical benefits VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide FDA Approval Status 2026:

Moreover, efpeglenatide therapy reduced the risk of CV disease by about 27% compared to the placebo in the Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) study [51]

GLP-1s reduce inflammatory markers like CRP and IL-6

During your consultation, our team will outline your customized plan and discuss transparent pricing

When in doubt, contacting a pharmacist or healthcare provider is the safest option

The key question will be durability: long-term tolerability, adherence, safety, cost, and whether these outcomes can be maintained outside highly selected trial populations

Competing interests Nik Krajnc: has participated in meetings sponsored by, received speaker honoraria or travel funding from BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)